Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC)

Vaccination remains the leading strategy against COVID-19 worldwide. BNT162b2 is among the first licensed vaccines with high effectiveness. However, the role of antibody and cell immunity response monitoring after vaccination remains unclear. We conducted a 6-month prospective study involving the em...

Descripción completa

Detalles Bibliográficos
Autores principales: Palacka, Patrik, Pol’anová, Monika, Svobodová, Alena, Žigmond, Jan, Zanchetta, Katarína, Gombárová, Vlasta, Vulganová, Martina, Slopovský, Ján, Obertová, Jana, Drgoňa, Ľuboš, Mego, Michal, Pechan, Juraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026370/
https://www.ncbi.nlm.nih.gov/pubmed/35455308
http://dx.doi.org/10.3390/vaccines10040558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026370/
https://www.ncbi.nlm.nih.gov/pubmed/35455308
http://dx.doi.org/10.3390/vaccines10040558

Ejemplares similares